Analysis and clearing the real clinical neurological relentless disease.

Analysis and clearing the real clinical neurological relentless disease. - Analysis and clearing the real clinical neurological relentless disease.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047103

Enrollment

1500

Registered

2022-04-01

Start date

2019-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distal myopathy, SBMA, ALS, Crow-Fukase syndrome, PLS, Myopathy with rimmed vacuoles, CMT, MG, PSP, PML, SCD, MSA, CBD, MS, NMO, PD, CIDP, MMN, Moyamoya disease, Alexander disease, muscle dystrophy, AERRPS, fragile X syndrome, TIA, or ischemic stroke

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Distal myopathy SBMA, ALS, Crow-Fukase syndrome, PLS, rimmed vacuole myopathy, CMT, MG, PDP, PML, SCD, MSA, CBD, MS, NMO, PD, CIDP, MMN, Moyamoya disease, AERRPS, fragile X syndrome, TIA, or ischemic stroke diagnosed patient.

Exclusion criteria

Exclusion criteria: MRI impossible patient.

Design outcomes

Primary

Measure	Time frame
Drug information, mRS, cardiovascular event, and mortality at 6M, 12M, 24M, 36M, 48M, and 60M after registration.	—

Countries

Japan

Contacts

Public ContactKosuke Matsuzono

Jichi Medical University Division of Neurology, Department of Medicine

kmatsuzono51@jichi.ac.jp0285587352

Outcome results